Loading...
•
Jun 30, 2022
Pacira Q2 2022 Earnings Report
Reported preliminary net product sales for July 2022.
Key Takeaways
Pacira BioSciences reported preliminary net product sales of $50.2 million for July 2022. EXPAREL sales grew, and ZILRETTA continued to perform well in its early growth stage. The company is not providing 2022 revenue or gross margin guidance at this time given the continued uncertainty around labor shortages, COVID-19, and the pace of recovery for the elective surgery market.
Net product sales for July 2022 were $50.2 million.
EXPAREL net product sales were $40.9 million, with average daily sales 105 percent of July 2021.
ZILRETTA net product sales were $8.2 million for July 2022.
iovera° net product sales were $1.1 million for July 2022.
Revenue by Segment
Forward Guidance
The company is not providing 2022 revenue or gross margin guidance at this time given the continued uncertainty around labor shortages, COVID-19, and the pace of recovery for the elective surgery market.
Challenges Ahead
- Continued uncertainty around labor shortages
- COVID-19 pandemic impact
- Pace of recovery for the elective surgery market
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...